These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2601075)
1. [Clinicopathological study on microscopic urinalysis as screening for malignant cells]. Kawabe T; Kaneoka A; Koichi K; Murakami N; Kuroki T; Kinugasa M; Miyake S; Takasu K Rinsho Byori; 1989 Oct; 37(10):1167-72. PubMed ID: 2601075 [TBL] [Abstract][Full Text] [Related]
2. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification. Whisnant RE; Bastacky SI; Ohori NP Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093 [TBL] [Abstract][Full Text] [Related]
3. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727 [TBL] [Abstract][Full Text] [Related]
4. Analysis of urine cytology at a community hospital. Mansoor I J Ayub Med Coll Abbottabad; 2003; 15(2):20-3. PubMed ID: 14552242 [TBL] [Abstract][Full Text] [Related]
5. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University. Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356 [TBL] [Abstract][Full Text] [Related]
6. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Wiener HG; Vooijs GP; van't Hof-Grootenboer B Acta Cytol; 1993; 37(2):163-9. PubMed ID: 8465635 [TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological study of urinary bladder tumors. Clinical evaluation of immunohistochemistry in urine cytology]. Nagata Y; Kinoshita H; Kawamura N; Sasadaira S Hinyokika Kiyo; 1985 Nov; 31(11):1931-7. PubMed ID: 4091136 [TBL] [Abstract][Full Text] [Related]
15. Screening and monitoring for bladder cancer: refining the use of NMP22. Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827 [TBL] [Abstract][Full Text] [Related]
16. [Clinical study of urinary cytology in bladder tumors--analysis of factors related with positivity of urinary cytology]. Tanaka K; Takashi M; Sahashi M; Shimoji T; Miyake K; Koshikawa T; Shiral T; Kawashima K; Nakajima N; Hamajima N Hinyokika Kiyo; 1990 Jan; 36(1):7-11. PubMed ID: 1689930 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of atypical urine cytology progression to malignancy. Muus Ubago J; Mehta V; Wojcik EM; Barkan GA Cancer Cytopathol; 2013 Jul; 121(7):387-91. PubMed ID: 23536358 [TBL] [Abstract][Full Text] [Related]
18. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek]. Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610 [TBL] [Abstract][Full Text] [Related]
19. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780 [TBL] [Abstract][Full Text] [Related]
20. Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma. Bhatia A; Dey P; Kumar Y; Gautam U; Kakkar N; Srinivasan R; Nijhawan R Cytopathology; 2007 Apr; 18(2):84-6. PubMed ID: 17397492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]